These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23973117)

  • 1. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.
    Endris V; Penzel R; Warth A; Muckenhuber A; Schirmacher P; Stenzinger A; Weichert W
    J Mol Diagn; 2013 Nov; 15(6):765-75. PubMed ID: 23973117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
    Deeb KK; Hohman CM; Risch NF; Metzger DJ; Starostik P
    Arch Pathol Lab Med; 2015 Jul; 139(7):913-21. PubMed ID: 26125431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Screening for EGFR mutations in lung cancer by a novel real-time PCR with double-loop probe and Sanger DNA sequencing].
    Zhang HP; Ruan L; Zheng LM; Bai DY; Zhang HF; Liao YQ; Ding Y
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):28-32. PubMed ID: 23648296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue.
    Fassunke J; Haller F; Hebele S; Moskalev EA; Penzel R; Pfarr N; Merkelbach-Bruse S; Endris V
    Int J Mol Med; 2015 Nov; 36(5):1233-43. PubMed ID: 26352389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 2-year experience with EGFR mutation analysis of small diagnostic samples.
    Hlinkova K; Babal P; Berzinec P; Majer I; Mikle-Barathova Z; Piackova B; Ilencikova D
    Diagn Mol Pathol; 2013 Jun; 22(2):70-5. PubMed ID: 23628817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of different massive parallel sequencing platforms for mutation profiling in formalin-fixed and paraffin-embedded samples].
    Jiang RR; Wang YJ; Teng XD; Xiao L; Bu H; Ye F
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):591-596. PubMed ID: 30107663
    [No Abstract]   [Full Text] [Related]  

  • 7. Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors.
    Leary AF; Castro DG; Nicholson AG; Ashley S; Wotherspoon A; O'Brien ME; Popat S
    Eur J Cancer; 2012 Jan; 48(1):61-7. PubMed ID: 22036089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
    de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
    PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis.
    Smith GD; Chadwick BE; Willmore-Payne C; Bentz JS
    J Clin Pathol; 2008 Apr; 61(4):487-93. PubMed ID: 17908804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
    Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
    Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.
    Cohen V; Agulnik JS; Jarry J; Batist G; Small D; Kreisman H; Tejada NA; Miller WH; Chong G
    Cancer; 2006 Dec; 107(12):2858-65. PubMed ID: 17096434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
    Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
    Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
    Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A
    Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
    Cushman-Vokoun AM; Crowley AM; Rapp SA; Greiner TC
    Am J Clin Pathol; 2013 Jul; 140(1):7-19. PubMed ID: 23765529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing.
    Isaka M; Serizawa M; Kenmotsu H; Koh Y; Takahashi S; Maniwa T; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Abe M; Hayashi I; Nakajima T; Yamamoto N; Takahashi T; Ohde Y
    Clin Lung Cancer; 2017 Sep; 18(5):519-526.e1. PubMed ID: 28057436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.
    König K; Peifer M; Fassunke J; Ihle MA; Künstlinger H; Heydt C; Stamm K; Ueckeroth F; Vollbrecht C; Bos M; Gardizi M; Scheffler M; Nogova L; Leenders F; Albus K; Meder L; Becker K; Florin A; Rommerscheidt-Fuss U; Altmüller J; Kloth M; Nürnberg P; Henkel T; Bikár SE; Sos ML; Geese WJ; Strauss L; Ko YD; Gerigk U; Odenthal M; Zander T; Wolf J; Merkelbach-Bruse S; Buettner R; Heukamp LC
    J Thorac Oncol; 2015 Jul; 10(7):1049-57. PubMed ID: 26102443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis.
    Hu C; Liu X; Chen Y; Sun X; Gong Y; Geng M; Bi L
    Oncol Rep; 2012 Nov; 28(5):1815-21. PubMed ID: 22923193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?
    Kim ST; Jung HY; Sung JS; Jo UH; Tanaka T; Hagiwara K; Park KH; Shin SW; Kim JS; Kim YH
    Am J Clin Oncol; 2013 Feb; 36(1):57-63. PubMed ID: 22237146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 2 real-time PCR assays for in vitro diagnostic use in the rapid and multiplex detection of EGFR gene mutations in NSCLC.
    Wong AT; To RM; Wong CL; Chan WK; Ma ES
    Diagn Mol Pathol; 2013 Sep; 22(3):138-43. PubMed ID: 23846439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.